{
    "ticker": "PCSA",
    "name": "Processa Pharmaceuticals, Inc.",
    "description": "Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. Founded in 2016 and headquartered in Richmond, Virginia, the company aims to address the challenges in treating rare diseases and conditions through its proprietary drug formulations. Processa's lead product candidate, PCS499, is designed to treat gastrointestinal diseases, particularly those caused by infectious agents. The company utilizes a unique approach to drug development by leveraging existing compounds and reformulating them to improve efficacy and safety profiles. With a commitment to patient-centric solutions, Processa is dedicated to advancing its pipeline through rigorous clinical trials and collaborations with healthcare partners. The company's mission is to enhance the quality of life for patients by delivering effective treatments that address serious health concerns, while also maintaining a focus on ethical clinical practices and regulatory compliance. As Processa continues to expand its research and development efforts, it remains steadfast in its goal of bringing innovative therapies to market that can make a significant difference in the lives of patients suffering from debilitating conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Richmond, Virginia, USA",
    "founded": "2016",
    "website": "https://www.processapharmaceuticals.com",
    "ceo": "David Young",
    "social_media": {
        "twitter": "https://twitter.com/ProcessaPharma",
        "linkedin": "https://www.linkedin.com/company/processa-pharmaceuticals/"
    },
    "investor_relations": "https://www.processapharmaceuticals.com/investor-relations",
    "key_executives": [
        {
            "name": "David Young",
            "position": "CEO"
        },
        {
            "name": "Joseph M. Maffei",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "PCS499"
            ]
        },
        {
            "category": "Gastrointestinal",
            "products": [
                "PCS128"
            ]
        }
    ],
    "seo": {
        "meta_title": "Processa Pharmaceuticals, Inc. | Innovative Therapies for Unmet Medical Needs",
        "meta_description": "Explore Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with unmet medical needs.",
        "keywords": [
            "Processa Pharmaceuticals",
            "Biotechnology",
            "Pharmaceuticals",
            "Clinical Trials",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Processa Pharmaceuticals focus on?",
            "answer": "Processa Pharmaceuticals focuses on developing innovative therapies for patients with unmet medical needs, particularly in the areas of oncology and gastrointestinal diseases."
        },
        {
            "question": "Who is the CEO of Processa Pharmaceuticals?",
            "answer": "David Young is the CEO of Processa Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Processa headquartered?",
            "answer": "Processa Pharmaceuticals is headquartered in Richmond, Virginia, USA."
        },
        {
            "question": "What is the lead product candidate of Processa?",
            "answer": "Processa's lead product candidate is PCS499, aimed at treating gastrointestinal diseases."
        },
        {
            "question": "When was Processa Pharmaceuticals founded?",
            "answer": "Processa Pharmaceuticals was founded in 2016."
        }
    ],
    "competitors": [
        "NTEC",
        "ADMA",
        "AXSM",
        "SNDX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "MRNA",
        "VRTX"
    ]
}